Social Europe

  • EU Forward Project
  • YouTube
  • Podcast
  • Books
  • Newsletter
  • Membership

Challenging patents key to make Covid-19 vaccine work for all

Kateřina Konečná 2nd July 2020

Finding a vaccine against the coronavirus is a biochemical challenge. Ensuring universal access to it, however, is a political choice.

Covid-19 vaccine, pharamaceutical companies, patents
Kateřina Konečná

Since the outbreak of Covid-19, the search for effective treatments and a vaccine to stem the spread of the pandemic has generated much political debate and many headlines. The race to find a vaccine has been particularly fierce among big pharmaceutical companies competing to become the first to commercialise it on the market. According to the New York Times, more than 135 vaccines are being developed, with two reaching the phase of large-scale efficacy tests—the final stage before deployment.

These companies are prime recipients of billions of euro in public money to support research and development to find a vaccine. The European Commission, through its Coronavirus Global Response, has raised €7.4 billion towards this end.

A major motivation for many of these efforts is the desire to find a cure for the pandemic that has infected millions of people around the world, killed hundreds of thousands, and disproportionately affected the most vulnerable. This however is only part of the picture.

First-mover advantage

Big pharmaceutical corporates are aggressively seeking what in the business world is known as ‘first-mover advantage’. The risk is that the first to develop an effective Covid-19 vaccine files for a patent which could make it sole supplier. Shareholders are pouring billions into these companies, in the hope of reaping big dividends.

Such exclusivity usually applies for 20 years but companies are known to manipulate the system to secure extensions. They can make minor changes, including to the colour of a pill, to renew a patent—changes which may not have benefits for patients but are sufficient to extend control over the drug and who can thus have access to it.



Don't miss out on cutting-edge thinking.


Join tens of thousands of informed readers and stay ahead with our insightful content. It's free.



Crucially, patents allow businesses to set prices—extremely high prices for first-mover pharmaceutical companies able to exploit the absence of alternatives in the market. This artificial inflation drives up costs for our public healthcare systems and increases the proportion of public money going to multinational companies, many based abroad, turning access to lifesaving drugs from a universal right into a privilege. Private health has already flourished in some European Union countries at the behest of the ‘troika’ (of the commission, the European Central Bank and the International Monetary Fund) supervising bailout programmes.

The current arrangements mean that those who are able to pay for drugs will obtain privileged access to a Covid-19 vaccine. Those unable to pay will be left stranded. We have seen how this story ends. An unjust and unequal system will mean millions of lost lives.

Universal access

But it needn’t be this way. Alternatives exist. Putting the public good above private interests means respecting the right to cure in public healthcare systems with universal access.

I am greatly inspired by the actions of the freedom-fighter, and South Africa’s first democratically-elected president, Nelson Mandela, who in the 1990s challenged the international patents system and the predatory behaviour of pharmaceutical companies. Mandela accused big companies of exploitation by charging exorbitant prices for HIV-AIDS drugs. He and his successor circumvented international patent rules to allow manufacturers to copy expensive drugs, delivering lower costs and saving lives.

Multinational corporations, backed by the US government, took the South African government to court, with Mandela as first defendant. Following international uproar, supported by a vibrant grassroots campaign, the drug companies however dropped the case, marking a huge victory for the right to cure.

Guarantees needed

The European Commission president, Ursula von der Leyen, has said that a Covid-19 vaccine would be universally accessible. But she has given no assurances as to how that would happen.

We need guarantees. The current system is broken. We cannot afford to lose more lives because of some companies’ desire to treat our health as a profitable commodity.

A progressive alliance across Europe, in which I take part, has launched a campaign to demand, first, that the EU condition research grants to pharmaceutical companies on universal access and, secondly, that the discriminatory and unjust patenting system be reformed, drawing on alternatives such as a universal patent pool.

A Covid-19 vaccine must be a public good. We have a right to cure.

Kateřina Konečná

Kateřina Konečná (KSČM, Czechia) is an MEP with the Left group in the European Parliament (GUE/NGL).

Harvard University Press Advertisement

Social Europe Ad - Promoting European social policies

We need your help.

Support Social Europe for less than €5 per month and help keep our content freely accessible to everyone. Your support empowers independent publishing and drives the conversations that matter. Thank you very much!

Social Europe Membership

Click here to become a member

Most Recent Articles

u4219834670 4977 8362 2b68e3507e6c 2 Europe’s Far Right Copies Trump—And It’s WorkingPaul Mason
u421983467645c be21 1cdd415d1c01 2 America’s Systemic Chaos Strategy: Europe Must Forge a New PathMario Pianta
u42198346ae 124dc10ce3a0 0 When Ideology Trumps Economic InterestsDani Rodrik
u4219834676e9f0d82cb8a5 2 The Competitiveness Trap: Why Only Shared Prosperity Delivers Economic Strength—and Resilience Against the Far RightMarija Bartl

Most Popular Articles

u4219834647f 0894ae7ca865 3 Europe’s Businesses Face a Quiet Takeover as US Investors CapitaliseTej Gonza and Timothée Duverger
u4219834674930082ba55 0 Portugal’s Political Earthquake: Centrist Grip Crumbles, Right AscendsEmanuel Ferreira
u421983467e58be8 81f2 4326 80f2 d452cfe9031e 1 “The Universities Are the Enemy”: Why Europe Must Act NowBartosz Rydliński
u42198346761805ea24 2 Trump’s ‘Golden Era’ Fades as European Allies Face Harsh New RealityFerenc Németh and Peter Kreko

Foundation for European Progressive Studies Advertisement

Spring Issues

The Summer issue of The Progressive Post is out!


It is time to take action and to forge a path towards a Socialist renewal.


European Socialists struggle to balance their responsibilities with the need to take bold positions and actions in the face of many major crises, while far-right political parties are increasingly gaining ground. Against this background, we offer European progressive forces food for thought on projecting themselves into the future.


Among this issue’s highlights, we discuss the transformative power of European Social Democracy, examine the far right’s efforts to redesign education systems to serve its own political agenda and highlight the growing threat of anti-gender movements to LGBTIQ+ rights – among other pressing topics.

READ THE MAGAZINE

Hans Böckler Stiftung Advertisement

WSI Report

WSI Minimum Wage Report 2025

The trend towards significant nominal minimum wage increases is continuing this year. In view of falling inflation rates, this translates into a sizeable increase in purchasing power for minimum wage earners in most European countries. The background to this is the implementation of the European Minimum Wage Directive, which has led to a reorientation of minimum wage policy in many countries and is thus boosting the dynamics of minimum wages. Most EU countries are now following the reference values for adequate minimum wages enshrined in the directive, which are 60% of the median wage or 50 % of the average wage. However, for Germany, a structural increase is still necessary to make progress towards an adequate minimum wage.

DOWNLOAD HERE

S&D Group in the European Parliament advertisement

Cohesion Policy

S&D Position Paper on Cohesion Policy post-2027: a resilient future for European territorial equity

Cohesion Policy aims to promote harmonious development and reduce economic, social and territorial disparities between the regions of the Union, and the backwardness of the least favoured regions with a particular focus on rural areas, areas affected by industrial transition and regions suffering from severe and permanent natural or demographic handicaps, such as outermost regions, regions with very low population density, islands, cross-border and mountain regions.

READ THE FULL POSITION PAPER HERE

ETUI advertisement

HESA Magazine Cover

With a comprehensive set of relevant indicators, presented in 85 graphs and tables, the 2025 Benchmarking Working Europe report examines how EU policies can reconcile economic, social and environmental goals to ensure long-term competitiveness. Considered a key reference, this publication is an invaluable resource for supporting European social dialogue.

DOWNLOAD HERE

Eurofound advertisement

Ageing workforce
The evolution of working conditions in Europe

This episode of Eurofound Talks examines the evolving landscape of European working conditions, situated at the nexus of profound technological transformation.

Mary McCaughey speaks with Barbara Gerstenberger, Eurofound's Head of Unit for Working Life, who leverages insights from the 35-year history of the European Working Conditions Survey (EWCS).

Listen to the episode for free. Also make sure to subscribe to Eurofound Talks so you don’t miss an episode!

LISTEN NOW

Social Europe

Our Mission

Team

Article Submission

Advertisements

Membership

Social Europe Archives

Themes Archive

Politics Archive

Economy Archive

Society Archive

Ecology Archive

Miscellaneous

RSS Feed

Legal Disclosure

Privacy Policy

Copyright

Social Europe ISSN 2628-7641

BlueskyXWhatsApp